Literature DB >> 21642436

Oxidation of 3,4-dihydroxyphenylacetaldehyde, a toxic dopaminergic metabolite, to a semiquinone radical and an ortho-quinone.

David G Anderson1, S V Santhana Mariappan, Garry R Buettner, Jonathan A Doorn.   

Abstract

The oxidation and toxicity of dopamine is believed to contribute to the selective neurodegeneration associated with Parkinson disease. The formation of reactive radicals and quinones greatly contributes to dopaminergic toxicity through a variety of mechanisms. The physiological metabolism of dopamine to 3,4-dihydroxyphenylacetaldehyde (DOPAL) via monoamine oxidase significantly increases its toxicity. To more adequately explain this enhanced toxicity, we hypothesized that DOPAL is capable of forming radical and quinone species upon oxidation. Here, two unique oxidation products of DOPAL are identified. Several different oxidation methods gave rise to a transient DOPAL semiquinone radical, which was characterized by electron paramagnetic resonance spectroscopy. NMR identified the second oxidation product of DOPAL as the ortho-quinone. Also, carbonyl hydration of DOPAL in aqueous media was evident via NMR. Interestingly, the DOPAL quinone exists exclusively in the hydrated form. Furthermore, the enzymatic and chemical oxidation of DOPAL greatly enhance protein cross-linking, whereas auto-oxidation results in the production of superoxide. Also, DOPAL was shown to be susceptible to oxidation by cyclooxygenase-2 (COX-2). The involvement of this physiologically relevant enzyme in both oxidative stress and Parkinson disease underscores the potential importance of DOPAL in the pathogenesis of this condition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21642436      PMCID: PMC3143656          DOI: 10.1074/jbc.M111.249532

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  The role of oxidative stress in amyotrophic lateral sclerosis and Parkinson's disease.

Authors:  Athan Baillet; Vanessa Chanteperdrix; Candice Trocmé; Pierre Casez; Catherine Garrel; Gérard Besson
Journal:  Neurochem Res       Date:  2010-06-10       Impact factor: 3.996

2.  Observation of an unusual electronically distorted semiquinone radical of PCB metabolites in the active site of prostaglandin H synthase-2.

Authors:  Orarat Wangpradit; Edelmiro Moman; Kevin B Nolan; Garry R Buettner; Larry W Robertson; Gregor Luthe
Journal:  Chemosphere       Date:  2010-09-16       Impact factor: 7.086

3.  Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections.

Authors:  T G Hastings; D A Lewis; M J Zigmond
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

Review 4.  COX-2 and neurodegeneration in Parkinson's disease.

Authors:  P Teismann; M Vila; D-K Choi; K Tieu; D C Wu; V Jackson-Lewis; S Przedborski
Journal:  Ann N Y Acad Sci       Date:  2003-06       Impact factor: 5.691

5.  Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration.

Authors:  Anna L Bartels; Klaus L Leenders
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

6.  Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease.

Authors:  M B Mattammal; R Strong; V M Lakshmi; H D Chung; A H Stephenson
Journal:  J Neurochem       Date:  1995-04       Impact factor: 5.372

7.  Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol.

Authors:  Jennifer N Rees; Virginia R Florang; Laurie L Eckert; Jonathan A Doorn
Journal:  Chem Res Toxicol       Date:  2009-07       Impact factor: 3.739

8.  Oxidation of 4-chlorobiphenyl metabolites to electrophilic species by prostaglandin H synthase.

Authors:  Orarat Wangpradit; Lynn M Teesch; S V Santhana Mariappan; Michael W Duffel; Karin Norstrom; Larry W Robertson; Gregor Luthe
Journal:  Chem Res Toxicol       Date:  2009-01       Impact factor: 3.739

9.  The active site cysteine of the proapoptotic protein glyceraldehyde-3-phosphate dehydrogenase is essential in oxidative stress-induced aggregation and cell death.

Authors:  Hidemitsu Nakajima; Wataru Amano; Akikazu Fujita; Ayano Fukuhara; Yasu-Taka Azuma; Fumiaki Hata; Takashi Inui; Tadayoshi Takeuchi
Journal:  J Biol Chem       Date:  2007-07-05       Impact factor: 5.157

Review 10.  Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases.

Authors:  William J Burke; Shu Wen Li; Hyung D Chung; David A Ruggiero; Bruce S Kristal; Eugene M Johnson; Patricia Lampe; Vijaya B Kumar; Mark Franko; Evelyn A Williams; Daniel S Zahm
Journal:  Neurotoxicology       Date:  2004-01       Impact factor: 4.294

View more
  46 in total

Review 1.  Monoamine oxidases in development.

Authors:  Chi Chiu Wang; Ellen Billett; Astrid Borchert; Hartmut Kuhn; Christoph Ufer
Journal:  Cell Mol Life Sci       Date:  2012-07-11       Impact factor: 9.261

2.  Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration.

Authors:  David S Goldstein; Courtney Holmes; Patti Sullivan; Deborah C Mash; Ellen Sidransky; Alessandro Stefani; Irwin J Kopin; Yehonatan Sharabi
Journal:  Parkinsonism Relat Disord       Date:  2015-07-17       Impact factor: 4.891

Review 3.  Concepts of scientific integrative medicine applied to the physiology and pathophysiology of catecholamine systems.

Authors:  David S Goldstein
Journal:  Compr Physiol       Date:  2013-10       Impact factor: 9.090

4.  Enhanced mitochondrial inhibition by 3,4-dihydroxyphenyl-acetaldehyde (DOPAL)-oligomerized α-synuclein.

Authors:  Theodore A Sarafian; Amneh Yacoub; Anastasia Kunz; Burkan Aranki; Grigor Serobyan; Whitaker Cohn; Julian P Whitelegge; Joseph B Watson
Journal:  J Neurosci Res       Date:  2019-08-16       Impact factor: 4.164

5.  Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.

Authors:  David S Goldstein; Patti Sullivan; Adele Cooney; Yunden Jinsmaa; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2015-02-25       Impact factor: 5.372

6.  Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.

Authors:  Lydia M M Vermeer; Virginia R Florang; Jonathan A Doorn
Journal:  Brain Res       Date:  2012-07-31       Impact factor: 3.252

7.  Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).

Authors:  Cristian Follmer; Eduardo Coelho-Cerqueira; Danilo Y Yatabe-Franco; Gabriel D T Araujo; Anderson S Pinheiro; Gilberto B Domont; David Eliezer
Journal:  J Biol Chem       Date:  2015-09-17       Impact factor: 5.157

8.  Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein.

Authors:  Jonathan W Werner-Allen; Sarah Monti; Jenna F DuMond; Rodney L Levine; Ad Bax
Journal:  Biochemistry       Date:  2018-02-15       Impact factor: 3.162

9.  Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease.

Authors:  David S Goldstein; Patti Sullivan; Adele Cooney; Yunden Jinsmaa; Rachel Sullivan; Daniel J Gross; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Neurochem       Date:  2012-10-25       Impact factor: 5.372

10.  Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells.

Authors:  David S Goldstein; Yunden Jinsmaa; Patti Sullivan; Courtney Holmes; Irwin J Kopin; Yehonatan Sharabi
Journal:  J Pharmacol Exp Ther       Date:  2015-11-16       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.